Daphne Karydas, director at Mineralys Therapeutics, Inc. ($MLYS), made two open market sales of common shares in the last year, totaling about $690,000. Her most recent sale was on November 13, 2025. These transactions rank 5,772nd among 11,678 insiders in our database, below the average sale amount of $8.6 million over 6.4 transactions. Karydas made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | Mineralys Therapeutics, Inc. | $MLYS | Karydas Daphne | Director | S | Common Stock | 3000 | $25.00 | 6,200.0000 | 79,139,956 | 32.61% | 0.00% |
| March 31, 2026 | Mineralys Therapeutics, Inc. | $MLYS | Karydas Daphne | Director | M | Common Stock | 3000 | $12.02 | 9,200.0000 | 79,139,956 | 48.39% | 0.00% |
| March 31, 2026 | Mineralys Therapeutics, Inc. | $MLYS | Karydas Daphne | Director | M | Stock Option | 3000 | $0.00 | 41,000.0000 | 79,139,956 | 6.82% | 0.00% |
| Feb. 19, 2026 | Mineralys Therapeutics, Inc. | $MLYS | Karydas Daphne | Director | A | Stock Option | 8300 | $0.00 | 8,300.0000 | 79,139,956 | 9999.99% | 0.01% |
| Feb. 19, 2026 | Mineralys Therapeutics, Inc. | $MLYS | Karydas Daphne | Director | A | Common Stock | 6200 | $0.00 | 6,200.0000 | 79,139,956 | 9999.99% | 0.01% |
| Nov. 13, 2025 | Mineralys Therapeutics, Inc. | $MLYS | Karydas Daphne | Director | M | Stock Option | 15000 | $0.00 | 17,900.0000 | 79,139,956 | 45.59% | 0.02% |
| Nov. 13, 2025 | Mineralys Therapeutics, Inc. | $MLYS | Karydas Daphne | Director | M | Common Stock | 15000 | $10.20 | 15,000.0000 | 79,139,956 | 9999.99% | 0.02% |
| Nov. 13, 2025 | Mineralys Therapeutics, Inc. | $MLYS | Karydas Daphne | Director | S | Common Stock | 10115 | $45.81 | 4,885.0000 | 79,139,956 | 67.43% | 0.01% |
| Nov. 13, 2025 | Mineralys Therapeutics, Inc. | $MLYS | Karydas Daphne | Director | S | Common Stock | 4885 | $46.36 | 0.0000 | 79,139,956 | 100.00% | 0.01% |
| June 12, 2025 | COMPASS Pathways plc | $CMPS | Karydas Daphne | Director | A | Share Option (Right to Buy) | 26000 | $0.00 | 26,000.0000 | 92,673,132 | 9999.99% | 0.03% |
| Feb. 13, 2025 | Mineralys Therapeutics, Inc. | $MLYS | Karydas Daphne | Director | A | Stock Option | 32900 | $0.00 | 32,900.0000 | 49,835,637 | 9999.99% | 0.07% |
| May 22, 2024 | Mineralys Therapeutics, Inc. | $MLYS | Karydas Daphne | Director | A | Stock Option | 22000 | $0.00 | 22,000.0000 | 0 | 9999.99% | 0.00% |
| May 9, 2024 | COMPASS Pathways plc | $CMPS | Karydas Daphne | Director | A | Share Option (Right to Buy) | 26000 | $0.00 | 26,000.0000 | 0 | 9999.99% | 0.00% |
| Sept. 18, 2023 | COMPASS Pathways plc | $CMPS | Karydas Daphne | Director | A | Share Option (Right to Buy) | 52000 | $0.00 | 52,000.0000 | 0 | 9999.99% | 0.00% |
| Sept. 13, 2023 | Mineralys Therapeutics, Inc. | $MLYS | Karydas Daphne | Director | A | Stock Option | 44000 | $0.00 | 44,000.0000 | 0 | 9999.99% | 0.00% |